Abdullah F. AlAsmari

Dr. Abdullah F. AlAsmari

Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2018 in BioMed Research International
Verified
Journal Article
Open access
PDF file
Fawaz AlasmariFawaz Alasmari
Fawaz Alasmari
MAMusaad Alshammari
Musaad Alshammari
Abdullah F. AlAsmariAbdullah F. AlAsmari
Abdullah F. AlAsmari
WAWael A. Alanazi
Wael A. Alanazi
KAKhalid Alhazzani
Khalid Alhazzani
Neuroinflammation has been observed in association with neurodegenerative diseases including Alzheimer’s disease (AD). In particular, a positive correlation has been documented between neuroinflammatory cytokine release and the progression of the AD, which suggests these cytokines are involved in AD pathophysiology. A histological hallmark of the AD is the presence of beta-amyloid (Aβ) plaques and tau neurofibrillary tangles. Beta-amyloid is generated by the sequential cleavage of beta (β) and gamma (γ) sites in the amyloid precursor protein (APP) by β- and γ-secretase enzymes and its accumulation can result from either a decreased Aβ clearance or increased metabolism of APP. Previous studies reported that neuroinflammatory cytokines reduce the efflux transport of Aβ, leading to elevated Aβ concentrations in the brain. However, less is known about the effects of neuroinflammatory mediators on APP expression and metabolism. In this article, we review the modulatory role of neuroinflammatory cytokines on APP expression and metabolism, including their effects on β- and γ-secretase enzymes.

1 May 2018 in International Immunopharmacology
Verified
Journal Article
Closed access
NANaif O. Al-Harbi
Naif O. Al-Harbi
ANAhmed Nadeem
Ahmed Nadeem
SASheikh Fayaz Ahmad
Sheikh Fayaz Ahmad
MAMoureq R. Alotaibi
Moureq R. Alotaibi
Abdullah F. AlAsmariAbdullah F. AlAsmari
Abdullah F. AlAsmari
KIKhalid E. Ibrahim
Khalid E. Ibrahim

1 November 2020 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
KPKartikay Prasad
Kartikay Prasad
FKFatima Khatoon
Fatima Khatoon
SRSummya Rashid
Summya Rashid
Nemat AliNemat Ali
Nemat Ali
Abdullah F. AlAsmariAbdullah F. AlAsmari
Abdullah F. AlAsmari
VKVijay Kumar
Vijay Kumar

15 December 2021 in Antioxidants
Verified
Journal Article
Open access
PDF file
Abdullah F. AlAsmariAbdullah F. AlAsmari
Abdullah F. AlAsmari
MAMetab Alharbi
Metab Alharbi
FAFaleh Alqahtani
Faleh Alqahtani
Fawaz AlasmariFawaz Alasmari
Fawaz Alasmari
MAMohammed AlSwayyed
Mohammed AlSwayyed
Nemat AliNemat Ali
Nemat Ali
Hepatotoxicity caused by chemotherapeutic drugs (e.g., doxorubicin) is of critical concern in cancer therapy. This study focused on investigating the modulatory effects of diosmin against doxorubicin-induced hepatotoxicity in Male Wistar rats. Male Wistar rats were randomly divided into four groups: Group I was served as control, Group II was treated with doxorubicin (20 mg/kg, intraperitoneal, i.p.), Group III was treated with a combination of doxorubicin and low-dose diosmin (100 mg/kg orally), and Group IV was treated with a combination of doxorubicin and high-dose diosmin (200 mg/kg orally) supplementation. A single dose of doxorubicin (i.p.) caused hepatic impairment, as shown by increases in the concentrations of serum alanine aminotransferase, aspartate aminotransferase, and alkaline phosphatase. Doxorubicin produced histological abnormalities in the liver. In addition, a single injection of doxorubicin increased lipid peroxidation and reduced glutathione, catalase, and superoxide dismutase (SOD) levels. Importantly, pre-treatment with diosmin restored hepatic antioxidant factors and serum enzymatic activities and reduced the inflammatory and apoptotic-mediated proteins and genes. These findings demonstrate that diosmin has a protective effect against doxorubicin-induced hepatotoxicity.

1 June 2018 in European Journal of Pharmacology
Verified
Journal Article
Closed access
SASheikh Fayaz Ahmad
Sheikh Fayaz Ahmad
MAMushtaq A. Ansari
Mushtaq A. Ansari
ANAhmed Nadeem
Ahmed Nadeem
SBSaleh A. Bakheet
Saleh A. Bakheet
MAMohammad Z. Alzahrani
Mohammad Z. Alzahrani
SASabry M. Attia
Sabry M. Attia

1 August 2023 in Saudi Pharmaceutical Journal
Verified
Journal Article
Open access
RARashid Ahmad
Rashid Ahmad
Momin KhanMomin Khan
Momin Khan
AAAftab Alam
Aftab Alam
AEAhmed A. Elhenawy
Ahmed A. Elhenawy
AQAbdul Qadeer
Abdul Qadeer
MAManzoor Ahmed
Manzoor Ahmed
Urease belongs to the family of amid hydrolases with two nickel atoms in their core structure. On the basis of literature survey, this research work is mainly focused on the study of bis-Schiff base derivatives of benzyl phenyl ketone nucleus. Synthesis of benzyl phenyl ketone based bis-Schiff bases in search of potent urease inhibitors. In the current work, bis-Schiff bases were synthesized through two steps reaction by reacting benzyl phenyl ketone with excess of hydrazine hydrate in ethanol solvent in the first step to get the desired hydrazone. In last, different substituted aromatic aldehydes were refluxed in catalytic amount of acetic acid with the desired hydrazone to obtain bis-Schiff base derivatives in tremendous yields. Using various spectroscopic techniques including FTIR, HR-ESI-MS, and 1H NMR spectroscopy were used to clarify the structures of the created bis-Schiff base derivatives. The prepared compounds were finally screened for their in-vitro urease inhibition activity. All the synthesized derivatives (3–9) showed excellent to less inhibitory activity when compared with standard thiourea (IC50 = 21.15 ± 0.32 µM). Compounds 3 (IC50 = 22.21 ± 0.42 µM), 4 (IC50 = 26.11 ± 0.22 µM) and 6 (IC50 = 28.11 ± 0.22 µM) were found the most active urease inhibitors near to standard thiourea among the synthesized series. Similarly, compound 5 having IC50 value of 34.32 ± 0.65 µM showed significant inhibitory activity against urease enzyme. Furthermore, three compounds 7, 8, and 9 exhibited less activity with IC50 values of 45.91 ± 0.14, 47.91 ± 0.14, and 48.33 ± 0.72 µM respectively. DFT used to calculate frontier molecular orbitals including; HOMO and LUMO to indicate the charge transfer from molecule to biological transfer, and MEP map to indicate the chemically reactive zone suitable for drug action. The electron localization function (ELF), non-bonding orbitals, AIM charges are also calculated. The docking study contributed to the analysis of urease protein binding.